Biofrontera (NASDAQ: BFRI) shares preliminary 2025 revenue data update

Rhea-AI Filing Summary

Biofrontera Inc. filed a current report to let investors know it has released a press release with preliminary, unaudited revenue figures for the fourth quarter and full year ended December 31, 2025. The press release, dated January 13, 2026, is included as Exhibit 99.1 and incorporated by reference.

The company notes that these revenue numbers are preliminary estimates and remain subject to its normal review processes, meaning the final fourth quarter results could differ materially. The disclosure is furnished rather than filed under the Exchange Act, limiting certain legal liabilities, and Biofrontera includes standard cautionary language that these forward‑looking statements reflect management’s views only as of the date of the report.

false 0001858685 0001858685 2026-01-13 2026-01-13 0001858685 BFRI:CommonStockParValue0.001PerShareMember 2026-01-13 2026-01-13 0001858685 BFRI:PreferredStockPurchaseRightsMember 2026-01-13 2026-01-13 0001858685 BFRI:WarrantsToPurchaseCommonStockMember 2026-01-13 2026-01-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): January 13, 2026

Biofrontera Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-40943		47-3765675
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

660 Main Street Woburn, Massachusetts		01801
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (781) 245-1325

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Exchange Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock, par value $0.001 per share		BFRI		The Nasdaq Stock Market LLC
Preferred Stock Purchase Rights		True		The Nasdaq Stock Market LLC
Warrants to purchase common stock		BFRIW		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (the “Exchange Act”) (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On January 13, 2026 Biofrontera Inc. (the “Company”) issued a press release announcing its preliminary unaudited revenues for the fourth quarter and full year ended December 31, 2025. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K (the “Form 8-K”) and is incorporated herein by reference.

The information contained in this Item 2.02 in this Form 8-K (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall such information be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

The financial information set forth in this Form 8-K reflects the Company’s current preliminary revenue estimates, is subject to the completion of its review process, and is subject to change. The Company’s fourth quarter results could differ materially from the preliminary estimates provided in this Form 8-K. You are cautioned not to place undue reliance on these forward-looking statements, which reflect management’s analysis only as of the date of this Form 8-K. The Company undertakes no obligation to publicly release the results of any revision or update of the forward-looking statements, except as required by law.

Item 9.01 Financial Statements and Exhibits.

99.1		Press Release dated January 13, 2026
104		Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

January 13, 2026 (Date)	Biofrontera Inc. (Registrant)
	/s/ E. Fred Leffler III
	E. Fred Leffler III
	Chief Financial Officer

FAQ

What did Biofrontera Inc. (BFRI) disclose in this 8-K?

Biofrontera Inc. furnished a press release announcing its preliminary unaudited revenues for the fourth quarter and full year ended December 31, 2025, as Exhibit 99.1.

Which period do Biofrontera’s preliminary revenues in this filing cover?

The preliminary unaudited revenues described relate to the fourth quarter and full year ended December 31, 2025.

How does Biofrontera characterize the financial data in this 8-K?

The company describes the revenue figures as preliminary, unaudited estimates that are subject to completion of its review process and may change.

Is the Biofrontera (BFRI) revenue information considered filed with the SEC?

No. The company states that the information in Item 2.02 and Exhibit 99.1 is being furnished, not filed, and is not subject to Section 18 liability under the Exchange Act.

What exhibit is attached to Biofrontera’s 8-K about preliminary revenues?

Exhibit 99.1 contains the press release dated January 13, 2026, setting out Biofrontera Inc.’s preliminary unaudited revenues.

Who signed Biofrontera Inc.’s 8-K reporting preliminary revenues?

The report was signed on behalf of Biofrontera Inc. by E. Fred Leffler III, Chief Financial Officer, dated January 13, 2026.